Study (year) | Design | No | Total FU | Age at onset (mean (SD)) | PD duration at entry (mean (SD)) | UPDRS-3 change pa (% max) |
DATATOP (1993)3 | CT | 199 | 6–21 months | 61.1 (9.5) | <5 years | 8.9 (8.3%) |
Olanow et al2 | CT | 40 | 14 months | 64.5 (1.8) | 3.2 (0.6) | 3.5 (3.2%) |
Parks. Study Group (1996)1 | CT | 66 | ≤12 months | 60.7 (10.9) | 1.7 (1.4) | 5.5 (5.1%) |
Shults et al (2002)47 | CT | 16 | ≤16 months | 63.1 (12.1) | <5 years | 6.5 (6.0%) |
ELLDOPA (2004)34 | CT | 90 | 42 weeks | 64.4 (10.4) | 0.4 (0.4) | 6.4 (5.9%) |
ADAGIO (2009)46 | CT | 545 | 36 weeks | 61.9 (9.7) | 0.4 (0.4) | 7.3 (4.1%)* |
Louis et al (1999)7 | C, P | 237 | Up to 8 years | 72.8 (10.5) | 6.8 (6.8) | 1.5 (1.4%) ‘on’ |
Goetz et al (2000)6 | H, P | 221 | Up to 4 years |
| 1.17 (both groups) |
|
Jankovic et al (2001)4 | H, P | 297 | Up to 17 years | 55.1 (NR) | 6.5 (NR) |
|
Alves et al8 | H, P | 89 | 8 years | 59.4 (9.7) | 8.8 (4.8) | 3.3 (3.1%) ‘on’ |
Schrag et al (2007)5 | H, P | 128 | 12 months | 57.6 (12) | 9.3 (7.4) | 3.3 (3.1%) ‘on’ |
Harrison et al (2009)48 | H, P | 162 | 2.2 years (mean) | 58.2 (11)† | 7 (6) | 0.3 (0.3%) ‘on’ |
Present study | C, I | 122 | 5.5 years (mean) | 69.5 (9.8) | From diagnosis | 2.24 (2.1%) ‘on’ |
The top panel displays results from the placebo arms of clinical trials, the lower panel results from longitudinal naturalistic studies.
* Rates of progression are estimated in the ‘off’ state unless otherwise indicated, and on the UPDRS-3 except for total UPDRS score.
† Data reported for a larger, cross sectional cohort of 888 cases within which the longitudinal cohort was nested.
C, community based; CT, clinical trial; FU, follow-up; H, hospital based; HYS-2, -3, Hoehn–Yahr stage 2, stage 3; I, incident; NR, not reported; P, prevalent; PD, Parkinson's disease; UPDRS, Unified Parkinson's Disease Rating Scale.